God is our Guide  Number 1 site for helping reverse

 

      

 
Home
Diagnosis
Treatment
Pathology
Variants
CIDP info
Fibromyalgia
IVIG
 Anti-inflammatory Diet
Burning  Feet Home
Services Page
Chronic Fatigue
Autoimmune diseases
Prognosis
Bible healing
Celiac disease
Spinal Injury Green tea

CIDP-neuropathy

Symptoms CIDP

Multi Focal Motor neuropathy

Treatment of GBS

Lewis Summer

Tips for CIDP

Axonal EMG

CIDP-EMG

Plasmapheresis

CIDP-INFO

CIDP-doctors

CIDP-Rituxan

CIDP-GBS-Handbook

CIDP-family issue

CIDP-Cyclosporin

Polyneuropathy

Peripheral Neuropathy

ALS & CIDP

Types of neuropathy

Treatment of alcoholic poly neuropathy

IgG subclass deficiency

IgG deficiency

Anticancer Diet

Myasthenia Diet

Food additives

No artificial sweetener in diet

Vinegar Benefits

Right Fat Diet

    

 CIDP in childhood CIDPUSA Foundation

   alternatives treatment of autoimmune disease  e-book 

Special Google Health Search

 

Review: 1
1: Pediatr Neurol. 2001 Mar;24(3):177-82.
Chronic inflammatory demyelinating polyneuropathy in childhood.
Connolly AM.
Department of Neurology, St. Louis Children's Hospital, Washington University of Medicine, St. Louis, Missouri 63110, USA.

Chronic inflammatory demyelinating polyneuropathy (CIDP) in children is relatively rare. However, it has been recognized for many years. In patients presenting with this disease, subacute onset of weakness usually develops over at least 2 months and often progresses to a loss of ambulation. Some children's initial presentations may mimic Guillain-Barre syndrome. Dysasthesias are common. Males are affected more than females, and antecedent illnesses or vaccinations occur in approximately half of patients. Physical examination reveals diffuse, proximal greater than distal weakness, with an absence or depression of muscle stretch reflexes. Electrophysiology confirms demyelination, and spinal fluid examination demonstrates albuminocytologic dissociation. The clinical presentation, diagnosis, and prognosis of childhood CIDP are reviewed. Treatment and immunologic features are also discussed in this article.

PMID: 11301217 [PubMed - indexed for MEDLINE]


 


2: Neuromuscul Disord. 2000 Aug;10(6):398-406.]
Childhood chronic inflammatory demyelinating polyneuropathy: clinical course and long-term outcome.
Ryan MM, Grattan-Smith PJ, Procopis PG, Morgan G, Ouvrier RA.
Department of Neurology, The Royal Alexandra Hospital for Children, Sydney, Australia.

We reviewed the clinical history, electrophysiologic and pathologic findings, and response to therapy of 16 children with chronic inflammatory demyelinating polyneuropathy. The majority presented with lower limb weakness. Sensory loss was uncommon. The illness was monophasic in seven children, relapsing in six, and three had a slowly progressive course. All patients were treated with immunosuppressive agents. In 11, the initial treatment was prednisolone. All had at least a short-term response but five went on to develop a relapsing course. Intravenous immunoglobulin was the initial treatment in four patients. Three responded rapidly, with treatment being stopped after a maximum of 5 months. In resistant chronic inflammatory demyelinating neuropathy, in addition to prednisolone and immunoglobulin, plasma exchange, azathioprine, cyclosporine, methotrexate, cyclophosphamide and pulse methylprednisolone were tried at different times in different patients. On serial neurophysiologic testing slowing of nerve conduction persisted for long periods after clinical recovery. Follow-up was for an average of 10 years. When last seen 14 patients were asymptomatic, two having mild residual deficits. Childhood chronic inflammatory demyelinating neuropathy responds to conventional treatment and generally has a favorable long-term outcome.

PMID: 10899445 [PubMed - indexed for MEDLINE]

: Eur J Paediatr Neurol. 1998;2(4):169-77.


 

Continue to next page of CIDPin children

message